Shire posts better-than-expected 13 pct rise in Q4 earnings

(Adds share price)
LONDON, Feb 11 (Reuters) – Shire(NasdaqGS: SHPG – news) , the London-listeddrugmaker buying Baxalta International for $32 billion,reported a better-than-expected 13 percent rise infourth-quarter earnings on Thursday, helped by strong sales ofits ADHD treatment Vyvanse.
The London-listed company clinched its biggest acquisitionto date in January, with a cash and shares deal to buy thespecialist in rare blood conditions, cancers and immune systemdisorders.
Chief Exe